Class action filed over Zyprexa side effects

25 April 2004

Parker & Waichman, Douglas & London and Hersh & Hersh have announced the filing of the first US nationwide class action law suit against Eli Lilly, on behalf of all persons residing in the USA who used the drugmaker's antipsychotic Zyprexa (olanzapine). The law suit was filed April 16 in the US District Court for the Eastern District of New York.

Zyprexa is currently the most popular atypical antipsychotic medication in the USA and, with fourth-quarter 2003 sales of $1.5 billion, is Lilly's best-selling drug. It has been linked to serious side effects including diabetes, hyperglycemia and pancreatitis, the law firms say.

The law suit seeks relief for Zyprexa patients who have already been diagnosed with side effects, as well as compensation for medical testing for all the people who have used the drug in the USA. The lawyers say that three plaintiffs who have been diagnosed with serious injuries have been named in the law suit. All of the plaintiffs developed diabetes after taking Zyprexa and one was diagnosed with pancreatitis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight